![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EMA Issues New Guidance on Variant COVID-19 Vaccines
EMA Issues New Guidance on Variant COVID-19 Vaccines
![EMA logo European Medicines Agency logo](https://www.fdanews.com/ext/resources/test/Drug-Images3/EMAlogo.jpg?t=1628546093&width=430)
The European Medicines Agency (EMA) has outlined in a new guidance how vaccine developers can seek revised authorizations for currently authorized COVID-19 vaccines to address threats from new variants of the SARS-CoV-2 virus.
Sponsors should begin communications with the agency approximately three months before filing a new submission, the EMA advised.
The guidance, which also applies to coronaviruses other than SAR-CoV-2, explains how sponsors can seek approval for vaccines that target mutated coronavirus strains. Separate product information needs to be submitted for each variant vaccine, the EMA said.
Upcoming Events
-
18Jul
-
21Oct